Method of treating precancerous and early stages of cancerous diseases of stomach

FIELD: medicine.

SUBSTANCE: invention relates to medicine and can be used for treatment of precancerous and early cancerous diseases of stomach. Step-by-step combined treatment is carried out. Pylobact, which includes two antibiotics: clarithromycin 500 mg and thinidasole 500 mg, and omeprazole 20 mg or combination of amoxicillin 500 mg units and metronidazole 250 mg are administered in accordance with the scheme. Simultaneously infusion of the herb "Wartwort" and tincture of the herb "Callisia fragrans" are administered in accordance with the scheme. In case of duodenogastric reflux anti-reflux medications are administered. After application of medications control test aimed at determination of quantitative change of microorganisms (Hp) in gastric mucosa is performed and on the basis of its results necessity of repeated scheme of treatment is determined.

EFFECT: method makes it possible to carry out Hp eradication and reduce damaging action of bile on gastric mucosa.

5 ex

 

The invention relates to medicine, namely to Oncology, and can be used for the treatment of precancerous and early stages of cancer of the stomach.

There is a method of combined treatment of patients with locally advanced gastric cancer (see RF patent №2194541 "Method of combined treatment of patients with locally advanced gastric cancer", publ. 20.12.2002,). There is a method of combined treatment of locally advanced gastric cancer is radical surgery combined with intraoperative radiation therapy, the infusion of cisplatin as radiosensibility to operations conducted two courses of systemic chemotherapy with interval between courses of 3 weeks according to the following scheme: methotrexate at a dose of 5 mg/m2intravenous, bolus 1 to day 5; carboplatin at a dose of 50 mg/m2in the form of a 45-minute intravenous infusion, 1 to day 5; 5-fluorouracil at a dose of 500 mg/m2in the form of a 3-hour continuous intravenous infusion, 1 to 5 days; 3 weeks after completion of chemotherapy, surgery, during which up to intraoperative radiation therapy (IORT) intravenous cisplatin at a dose of 15 mg/m2.

The proposed use of anticancer chemotherapy for treatment of locally advanced gastric cancer before surgery and spend two courses of chemotherapy the intervals between courses of 3 weeks with methotrexate, carboplatin, 1 to day 5 fluorouracil, after 3 weeks, surgery, during which impose cisplatin.

One of the main disadvantages of this method is that after such preoperative preparation of patients appears clinic intoxication and no data on blood, and after all this, patients are taken to the operation.

There is a method of treatment of cancer (see RF patent №2284184 "treatment of cancer", publ. 27.09.2006 year), which includes the oral administration of a combination of tegafur and uracil at a dose of tegafur 100-500 mg/m2/day in a molar ratio of tegafur and uracil 1:4; oral administration of 0.1-500 mg/kg/day folinovoy acid or its pharmaceutically acceptable salt; intravenous administration of paclitaxel and carboplatin dose of 10-300 mg/m2and 100-500 mg/m2accordingly, with paclitaxel and carboplatin is administered at day 1 of a 28-day cycle, and tegafur, uracil and polynovo acid or its pharmaceutically acceptable salt in 2-22-th days. Moreover 23-28-th day of the cycle constitute a break. When this treatment is repeated at least once.

The proposed method of treatment, in our opinion, leads to high toxicity in patients and does not lead to 100% recovery, but to a small remission, or is part of preoperative preparation. In this group of drugs has serious defects in the weave: hand of blood-forming organs - leukopenia, eritrotsitopeniya, thrombocytopenia, megablasta anemia. The digestive system - ulcerogenic action, perforate bowel disease, elevation of hepatic transaminases, vomiting, diarrhea. Cardiovascular - angina, myocardial infarction, sudden death. Nervous system - dizziness, weakness, ataxia, slurred speech. Dermatologic reactions - skin damage, alopecia. The osteoporosis. The reproductive system.

The task of the invention is to develop a method of treatment of precancerous and early stages of cancer of the stomach therapeutic method with minimal harm to the entire body of the person.

The effectiveness of the proposed method lies in the treatment of precancerous conditions and early stage cancer, in which a combined treatment: first erradicate on Helicobacter populating or weakening of its virulence as irritating agent on gastric mucosa, through the use of two antibiotics, otherwise remove chemical irritant factor - duodenogastric reflux (DR) bile, if diagnosed by endoscopy of the stomach(FGS), acting antireflux drugs with mandatory use of medicinal herbs "Kalliziya fragrans" and "Celandine" special CX is IU. It is known from information sources (Arwin LI From 100 infected with Helicobacter pylori stomach cancer occurs in two. Who are they? // Experimental. and the wedge. Gastroenterol. - 2004. No. 1 (special issue). - P.12-18; Erwin LI, Kapeller L.L., Isakov V.A. Morphological diagnosis of diseases of the stomach and intestines. - M.: Triad-H. 1998. - P80-85, 272; Baranska E.K., Ivashkin V.T. Clinical spectrum of precancerous stomach pathology // ROS. Journe. Gastroenterol., gepatol., coloproctol. - 2002. - So 12, No. 3. - P.7-14; Isakov V.A., Domaradsky IV of Helicobacter pylori infection. - M: Mediratta - M., 2003. - 412 S.; Pasechnikov E, Chukov SZ Early cancer of the upper gastrointestinal tract // Consilium medicum. - 2002. - Mgr. "Dyspepsia". - S-18), precancerous diseases, such as adenomatous polyps or dysplasia, not treated therapeutically, and only observed endoscopically: when the malignancy process are treated, usually by chemotherapy or by surgery.

The essence of the proposed method for the treatment of precancerous and early stages of cancer of the stomach is phased combined treatment: the first stage involves making Elobact one strip in the morning and after 8 hours at night, with each strip includes two antibiotics: clarithromycin 500 mg, and tinidazole 500 mg, and omeprazole 20 mg, or using a different combination antibiotic consisting of amoxicillin 500 mg units and m is nidazole 250 mg, 3 times a day before meals for 30 minutes, one of these drugs used for 7-14 days, while at the duodeno-reflux prescribe anti-reflux drugs, after application of drugs produce control study on quantitative changes in microorganisms (HP) in the gastric mucosa, and together with antibacterial drugs prescribed infusion of the herb greater Celandine" 2 tablespoon 3 times a day for 40 minutes before meals for 7 days; the second stage of treatment involves the use of tincture of herbs "Kalliziya fragrans" 1 teaspoonful 3 times a day before food for 40 minutes for 4 weeks, the third stage of treatment involves the use of an infusion of the herb greater Celandine" 2 tablespoon 3 times a day for 40 minutes before meals for 3 weeks; the fourth stage of treatment includes the use of tinctures from herbs "Kalliziya of fragrant" 1 teaspoonful 3 times a day for 40 minutes before meals for 3 weeks and then spend control study, the results of which determine the need for re-treatment regimen.

Infusion "Celandine" prepared as follows: 2 tablespoons pour 0.5 liters of boiling water for 6 hours, then squeeze, strain and put the infusion in the refrigerator. Tincture of "Callisia of fragrant" prepared as follows: 23-25 ring is asthenia "Callisia of fragrant" can be used together with leaves, which are finely cut and poured 0.5 liters of vodka. Infuse for 7 days in a dark place, then filtered. The resulting infusion should be used : 1 teaspoon 3 times a day for 40 minutes before a meal. In case of burning sensation in the mouth while receiving the infusion, add 1 tablespoon of boiled cold water.

New in the proposed invention is that in the treatment of precancerous conditions and early stage cancer is used combined treatment: first - erradicate on Helicobacter populating or weakening of its virulence as irritating agent on gastric mucosa, through the use of two antibiotics, otherwise remove chemical irritant factor - duodenogastric reflux (DR) bile, if diagnosed by endoscopy of the stomach, acting antireflux drugs with mandatory use of medicinal herbs "Kalliziya fragrans" and "Celandine" special of the proposed scheme.

Conducted by the applicant's analysis of the prior art, including searching by the patent and scientific and technical information sources, has allowed to establish that the applicant had not discovered similar, characterized by signs, identical with all the essential features of the claimed invention. Therefore, the claimed invention meets the condition of "novelty".

Invented the e meets the criterion of "industrial applicability", as it can be successfully applied in clinical practice.

The method of treatment of precancerous and early stages of cancer of the stomach is performed as follows: after endoscopic examination, with detection of precancerous and taking biopsy samples from this area, whether it be a polyp or leukoplakia, sent this material for histological examination and, as a rule, in all cases using test strips is Helicobacter populating (HP). After confirmation precancerous assigned to the proposed combined treatment. The first stage involves taking Elobact"strip in the morning and 8 hours later the strip at night, one bar consists of 2 antibiotics clarithromycin 500 mg, and tinidazole 500 mg, omeprazole 20 mg, the rate of medication 7-14 days. After applying this drug Helicobacter populating, in many cases, remained in the gastric mucosa, it was determined using heliotest strips. It is possible to use a different schema antibiotic consisting of amoxicillin 500 mg 3 times a day metronidazole 250 mg 3 times a day before meals for 30 minutes, taking drugs 7-14 days. However, microorganisms (HP) after the study remained on the mucous membrane, but in small numbers, it was observed by the intensity of staining heliotest strips. When DR prescribe anti-reflux ven the rata for example, reglan or motilium. Together with antibacterial drugs prescribed medicinal grass "Celandine" in the form of infusion 2 tablespoons 3 times a day for 40 minutes before meals for 7 days. The second stage Kalliziya fragrans" in the form of tincture 1 teaspoon 3 times a day before meals for 40 minutes at 4 weeks. The third stage - "Celandine" 2 tablespoons 3 times a day for 40 minutes before meals for 3 weeks. The third stage "Kalliziya of fragrant also 1 teaspoon 3 times a day for 40 minutes before meals, for 3 weeks. After the first session is the control esophagogastroduodenoscopy.

According to the observations after the first session in 30% of cases polyps disappear, the remaining decrease in size; if they were red, I get the pink color of the mucosa, hyperplasia, leukoplakia and dysplasia disappear completely, which is confirmed by histological studies.

Clinical example of application of the method.

After collecting history (which included complaints, history of disease, allergic anamnesis) of the patient laid on endoscopic table, in position on the left side. The insertion of the endoscope into the esophagus and consistently inspect the lining of the esophagus, stomach and duodenum. In the presence of suspicious entities with the mucous membrane of the organ biopsies to be taken, for example with the polyp, g is purpusii, leukoplakia, etc. usually with the help of an endoscopic forceps is taken 4-5 pieces and sent to the pathology lab for histological study. Typically, when precancerous diseases is the Helicobacter populating, so if any is appointed, the proposed combination of antibacterial agents operating on Helicobacter populating. The treatment of 55 patients with precancerous and 3 patients early stages of cancer diseases with successful recovery without complications on the human body.

Selected patients who refused surgical treatment, and also patients with polyps hemispherical or spherical shape, such polyps is impossible to throw endoscopic loop to remove polyps through the endoscope.

The treatment of 55 patients with precancerous diseases:

adenomatous polyps, giperplazirovannami polyps, leukoplakia, hyperplastic gastritis, metaplasia, dysplasia, and 3 cancer patients who refused categorically from surgical treatment.

1. Beetle N. M., born in 1952 Complaints (12.05.2006,) nausea after eating, sometimes pain and heaviness in the epigastrium. Esophagogastroduodenoscopy polyp antral type II, i.e. hemispherical shape with a size of 0.7×0.7 cm greater curvature of the stomach. Atrophic gastritis. Surface duodeni is. This resonance. Complete blood count(11.05.06 year): Hb - 117, L - 5,0*10, ESR - 6. HP (+++). Histology (17.05.2006,): fragments of adenomatous polyps and inflammatory infiltration in the stroma. Assigned to combined treatment: the first stage - metronidazole 250 mg 3 times for 30 minutes before a meal - 7days together with "Celandine" 2 tablespoon 3 times a day for 40 minutes before a meal; the second stage - "Kalliziya of fragrant" 1 teaspoonful 3 times a day for 40 minutes before meals for 4 weeks; the third stage - "Celandine" 2 tablespoon 3 times a day for 40 minutes before meals for 3 weeks; the fourth stage - "Kalliziya of fragrant" 1 teaspoonful 3 times a day for 40 minutes before meals for 3 weeks.

Control study conducted 20.10.2007, no Complaints. Esophagogastroduodenoscopy - complete polyp regression. Atrophic gastritis. Complete blood count: Hb - 126, L - 5,1*10, ESR - 7. 29.02.2008, no Complaints. Esophagogastroduodenoscopy: atrophic gastritis. HP(++).

Histology (05.03.2008,) - atrophic gastritis of the gastric mucosa. Control study - 25.05.2010, no Complaints. Esophagogastroduodenoscopy - atrophic gastritis.

Blood tests: ALT - 0,26, AST - 0,18, bilirubin - 18,8, indirect - 18,8. SRO - (-), seromucoid - (-), HB - 96, L - 3,8 .10, ESR - 15.

Final control study 16.06.2010, no Complaints. Esophagogastroduodenoscopy showed regression of the polyp. Blood tests - AST - 0,18, ALT - 0,26, bilirubin - 18,8, thymol test - 1,, SRO - (-), seromucoid - 0,18.

2. Avgustina M A., born in 1938 Complaints (23.01.07 g) burning sensation in the epigastrium after eating, belching air. Esophagogastroduodenoscopy: leukoplakia and hyperplasia of the antrum. Atrophic gastritis. HP(+++). Histology - poorly-differentiated adenocarcinoma of the stomach. Treatment: the first stage - Elobact strip in the morning and 8 hours later the strip at night for 7 days, at the same time "Celandine" 2 tablespoon for 40 minutes before a meal; the second stage - "Kalliziya of fragrant" 1 teaspoonful 3 times a day for 40 minutes before meals for 4 weeks; the third stage - "Celandine" 2 tablespoon 3 times a day for 40 minutes before meals for 3 weeks; the fourth stage - "Kalliziya of fragrant" 2 tablespoon 3 times in 40 minutes before meals for 3 weeks.

Control study from 6.03.07, Complaints - minor heartburn epigastric pain, belching air. Esophagogastroduodenoscopy - subtropically gastritis. This resonance. HP (++). Histology (21.03.08 year): atrophic gastritis areas of hyperplasia and inflammatory infiltration in the stroma.

Complaints (19.09.2008, on a small heartburn epigastric pain, belching air. Esophagogastroduodenoscopy: subtropically gastritis. This resonance. Extensive biopsy of the antrum. HP (+++). Histology N I - atrophic mucosa of the stomach and moderate infiltration in the stroma, the plethora of vessels. N II - OBRs the key of the gastric mucosa and events hyperplasia.

Assigned to the second treatment (28.01.2010,). No complaints. Esophagogastroduodenoscopy: Atrophic gastritis. Superficial duodenitis. Blood tests: AST - 0,2, ALT - 0,5, unconjugated bilirubin - 6.8, cholesterol - 4,4, Thymol test - 1,8, Veltman sample - 0.5 l.

The CBC - HB - 138 g/l, L - 3.2-10, ESR - 6, blood sugar and 6.2.

3. Shikova NS, born in 1954 Complaints (21.08.2009,) epigastric pain after meals, loss of appetite, nausea. Esophagogastroduodenoscopy:

Polyposis I-II - type (0,4×1.0 cm) of the lower third of the body and antrum of the stomach. Mixed gastritis (antral hyperplastic gastritis). Superficial duodenitis. The CBC - Hb - 142, L - 9,0*10, ESR - 3. Histology No. 7920 - fragments of adenomatous polyps of the stomach. NR - (+++). Assigned to combined treatment: the first stage - amoxicillin 500 mg 3 times a day, metronidazole 250 mg 3 times a day before meals, at the same time "Celandine" 2 tablespoon 3 times a day for 40 minutes before meals for 7 days. The second stage is assigned Kalliziya of fragrant" one teaspoon 3 times a day for 40 minutes for 4 weeks. The third stage - "Celandine" 2 tablespoon 3 times a day for 40 minutes before meals for 3 weeks. The fourth stage - "Kalliziya of fragrant" 1 teaspoonful 3 times a day for 40 minutes for 3 weeks.

Complaints (14.12.2009,) on the heaviness after a meal in the stomach. Esophagogastroduodenoscopy - Olips the lower third of the body and antral - type I-type II (9 polyps of 0.3×0.6 cm), the trend towards devolution. Subtropically gastritis. NR - (+++).

Appointed a second course of treatment. Complaints (16.04.2010,) and discomfort in the epigastrium. Esophagogastroduodenoscopy - three polyp hemispherical shape (type II) antrum (0,7×0.5 cm). Regression 6 polyps of the stomach. Subtropically gastritis. Pronounced duodenitis. Blood tests: ALT - 0,1, AST - 0,2, bilirubin - 23,6, indirect - 23,6, Thymol test - 1,2, SRO - (++), Hb - 142, L - 4.0*10, ESR - 5.

26.08.2009 ghistory: adenomatous polyps of the stomach. Assigned to the third course of treatment. No complaints (16.09.10 year). Esophagogastroduodenoscopy - regression of polyps antrum. HP (++).

22.09.2010, Histology - hyperplastic mucosa of the stomach with pockets intentially realignment glands, mild diffuse polymorphonucleocytes infiltration in the stroma, the foci of hemorrhage.

4. Gurov VV born in 1951 Complaints (31.05.2010) on heartburn and discomfort in the chest, especially after a meal. Esophagogastroduodenoscopy - Leukoplakia of the lower third of the esophagus. Esophagism the lower third of the esophagus. Mixed gastritis. Superficial duodenitis. Histological examination of Leukoplakia with focal dysplasia of epithelium - II stage. HP(+++). Prescribed treatment. The first stage is amoxicillin 500 mg 3 times a day, metronidazole 250 mg 3 times a day and one the belt "Celandine" 2 tablespoon 40 minutes before meals for 7 days. The second stage - "Kalliziya of fragrant" 1 teaspoonful 3 times a day for 40 minutes before meals for 4 weeks. The third stage - "Celandine" 2 tablespoon 3 weeks for 40 minutes before meals for 3 weeks. The fourth stage - "Kalliziya of fragrant" 1 teaspoonful 3 times a day for 40 minutes before meals for 3 weeks.

26.11.2010, no Complaints. ADFS - regression leukoplakia. The esophagism no. Subtropically gastritis. Superficial duodenitis. NR - (+++).

Blood: ACT - 0,22, ALT - 0,36, bilirubin - 14,5, Thymol test - 2,2, SLO - (-).

Histology (02.12.2010,) - hyperplastic stratified squamous epithelium.

5. Aginova N.T., born in 1940 Complaints (22.12.2008,) on pain and heaviness in the epigastrium after eating, burping rotten. Esophagogastroduodenoscopy - Polyposis (8 polyps) II-type III (0,5×2.0 cm) of the body and antrum of the stomach. Subtropically gastritis. Pronounced duodenitis. HP+microscopically. Histology - adenomatous polyp of the stomach with groups of polymorphism glands, homerenovation diffuse polymorphonucleocytes infiltration in the stroma, the centers of the surface erozirovanne.

Assigned to the same combined treatment. The first stage - Elobact and "Celandine" for 7 days, the second stage - "Kalliziya of fragrant" for 4 weeks, the third stage - "Celandine" for 3 weeks, the fourth stage - "Kalliziya of fragrant" for 3 weeks.

Control study 06.04.09 is. Complaints of heaviness in the stomach, sometimes occurring after a meal. Esophagogastroduodenoscopy: 4 polyp hemispherical shape II-type (0,4×0.5 cm) of the large curvature of the middle third of the body and the lesser curvature (of 0.3×0.4 cm) of the lower third of the body of the stomach in regression. Subtropically gastritis. Superficial duodenitis. Microscopically - HP is not revealed.

Complete blood count: Hb - 130, L - 3,940, ESR - 7. Hb - 130, L - 3,9*10, ESR - 7, bilirubin - 16,94, Alt - 0,5, AST - 0,98, Thymol test - 1,7, diastasis urine - 6,4.

The second course of treatment. Control study of 26.06.2009, complaints of constipation. Esophagogastroduodenoscopy - hyperplasia (0,2×0.3 cm) of the lesser curvature of the antrum, subtropically gastritis, superficial duodenitis. Esophagogastroduodenoscopy: single polyp II-type (0,3×0.4 cm) of the anterior wall of the antrum. Subtropically gastritis. Superficial duodenitis. Histology N 6468 - atrophic mucosa of the stomach with polymorphism glands, superficial glands hyperplasia with rebuilding their intestinal epithelium, stroma foci of hemorrhage.

Hold the third course of treatment. If there is a pathological process, then re-taken gastrobiopsija with the polyp, as well as the analysis of Helicobacter populating. In parallel was performed blood tests, abnormalities were not observed.

By the endoscopic observation in patients with 9-12 polyps, the cat is ryh histologically diagnosed adenomatous polyps of the stomach (according to literature data, they go in gastric cancer in 75% of cases, currently, the ratio of adenomatous polyps to giperplazirovannam increased significantly, after three courses of treatment completely polyps regressed.

During the treatment of 55 patients with a positive effect was observed in 55 cases, precancerous disease has been cured completely, it was confirmed endoscopically and histologically.

The method of treatment of precancerous and early stages of cancer of the stomach, including phased combined treatment, on the first stage of the adoption of Elobact one strip in the morning and after 8 h per night, with each strip includes two antibiotics: clarithromycin 500 mg, and tinidazole 500 mg, and omeprazole 20 mg, or antibiotics, consisting of amoxicillin 500 mg and metronidazole 250 mg 3 times a day before meals for 30 minutes, one of these drugs used for 7-14 days, while at the duodeno-reflux prescribe anti-reflux drugs, after application of drugs produce control study on quantitative changes in microorganisms (HP) in the gastric mucosa, and together with antibacterial drugs prescribed infusion of the herb greater Celandine" 2 tablespoon 3 times a day for 40 minutes before meals for 7 days, the second stage of treatment involves the use of tinctures from herbs Ka is lisia fragrans" 1 teaspoonful 3 times a day before meals for 40 min for 4 weeks, the third stage of treatment involves the use of an infusion of the herb greater Celandine" 2 tablespoon 3 times a day for 40 minutes before meals for 3 weeks, the fourth stage of treatment includes the use of tinctures from herbs "Kalliziya of fragrant" 1 teaspoonful 3 times a day for 40 minutes before meals for 3 weeks and then spend control study, the results of which determine the need to re-offer the combined regimens.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: present invention relates to crystalline forms A, B and F of racemic ilaprazole (2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]thionyl]-5-(1H-pyrrol-1-yl)-1H-benzimidazole). The invention also relates to a pharmaceutical composition based on crystalline ilaprazole and use of crystalline ilaprazole.

EFFECT: obtaining novel crystalline forms of ilaprazole which can be used to inhibit gastric acid secretion.

14 cl, 57 dwg, 39 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and concerns prevention of purulent-septic complications after radical mastectomy. For this purpose against the background of generally accepted complex therapy hypodermically at the level of vertebras Th II - Th VI medical mixture in composition: local anesthetic 1 ml, glucose 40% to 1 ml, 0.9% solution of sodium chloride 4 ml, glutoxim 3% 2 ml, is introduced. Procedure is carried out five times -a day before operation, on the first day after operation and then three times with 24 hour interval.

EFFECT: method ensures reduction of purulent-septic complication frequency as a result of efficient reduction of terms of lymphorrhea duration and correction of local immune-inflammatory reaction.

4 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a crystalline form of ilaprazole hydrate (2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulphinyl]-5-(1H-pyrrol-1-yl) 1H-benzimidazole). The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion, as well as a method of treating inflammatory gastrointestinal disorders.

EFFECT: novel crystalline form of ilaprazole hydrate is obtained.

7 cl, 21 dwg, 19 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to substituted sulphamide derivatives of formula I: , in which n, m, R1, R2a-c, R3, R4, R5 and R6 are as described in claim 1, in form of a racemate, enantiomers, diastereomers, mixtures of enantiomers or diastereomers or a separate enantiomer or diastereomer, bases and/or salts of physiologically compatible acids. The invention also relates to a method of producing said compounds, a medicinal agent having antagonist action on bradykinin receptor 1 (B1R), containing such compounds, use of such compounds to produce medicinal agents, as well as sulphamide-substituted derivatives selected from a group of compounds given in claim 8.

EFFECT: providing novel compounds which are suitable as pharmacologically active substances in medicinal agents for treating disorders or diseases which are at least partially transmitted through B1R receptors.

13 cl, 581 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a solid dispersion wherein revaprazan particles are surface-modified by a water-soluble polymer, a water-soluble saccharide, a surfactant or their mixture wherein the water-soluble polymer is specified in a group consisting of polyvinylpyrrolidone, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, polyethylene glycol, a water-soluble polyacrylic acid copolymer, polyvinyl alcohol or their mixture, and wherein the water-soluble saccharide is specified in a group consisting of lactose, white sugar, saccharose, mannitol, sorbitol, xylitol, trehalose, maltitol, dulcitol, inositol, dextrin, cyclodextrin and their mixture. The invention also refers to a method for preparing said solid dispersion. The present invention also presents a pharmaceutical composition containing the solid dispersion, and the method for producing the pharmaceutical composition.

EFFECT: invention provides improved solubility of revaprazan and reduced adhesion and agglutination properties.

16 cl, 4 dwg, 7 tbl, 55 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly gastoenterology, and concerns treating ulcerative colitis and Crohn's disease. That is ensured by the oral introduction of the probiotic Bifiform in dose 2-3 capcules. It is followed by the 4-5-fold introduction of mesenchymal stem cells in number 150-200 mil. cells in 0.5 to 1.5 ml into a mucous membrane of changed intestinal segments. Further, Bifiform is introduced in dose 1 capsule 3 times a day for 3 weeks.

EFFECT: method provides higher clinical effectiveness in said diseases.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to a pharmaceutical composition, particularly a composition for treating and/or preventing mucositis. The composition containing an effective amount of sanguinarine or chelerythrine in the form of a luteic acid salt mixed with appropriate carriers and/or excipients for treating and/or preventing mucositis. The chelerythrine and luteic acid salt. The sanguinarine and luteic acid salt. The use of sanguinarine or chelerythrine in the form of their lutec acid salts for preparing drugs for treating and/or preventing mucositis.

EFFECT: composition described above of sanguinarine or chelerythrine in the form of the lutec acid salts is effective for treating and/or preventing mucositis.

10 cl, 8 ex

FIELD: medicine.

SUBSTANCE: declared invention refers to an agent for treating ulcer including as an effective ingredient composite hydrotalcite in the form of particles, which contains zinc in the form of a solid solution and presented by formula (MgaZnb)1-xAlx(OH)2(An-1)x/n·H2O, wherein An-1 means CO32-, SO42- or Cl-, n is equal to 1 or 2, and x, a, b and m have the values fulfils the following conditions 0.18≤x≤0.4, 0.1≤a≤1, 0≤b≤0,5, 0≤m<1. Said agent may be presented in the granular or fine-grained form, suspension form or tableted form. The invention also refers to a method of treating peptic ulcer by the oral introduction of an effective amount of said hydrotalcite.

EFFECT: declared invention has an effective effect in treating peptic ulcer in an individual or a mammal, nor damaging a mucous membrane of internal walls of stomach, and possesses low probability of side effects.

17 cl, 6 tbl, 23 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are described new benzimidazole derivatives of general formula I wherein: R1 = CN, halogen or C(=O)CH3; R2 means methyl or H; R3=H or halogen; R4 and R5 independently mean methyl or ethyl, or R4 and R5 together with a carbon atom whereto attached form C3-6cycloalkyl or 5-6-member heterocycloalkyl; R6 and R7 independently mean H, halogen, methyl or ethyl; or their pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds, and their application in therapy.

EFFECT: compounds may be used in treating osteoarthritis, chronic tendinitis, pelvic pain and peripheral neuropathy, gastroesophageal reflux disease, irritable bowel syndrome and overactive bladder.

39 cl, 34 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.

EFFECT: there are produced new benzimidazole derivatives showing PPARγ modulatory activity.

41 cl, 2 dwg, 6 tbl, 76 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically dermatology, and may be used for treating experimental leprous infection. For the purpose for suppression of leprous mycobacteria propagation in mice pads infected intraplantarily by Shepard's method, therapeutic agents are used. The therapeutic agents are presented by a herbal tea. The tea contains ground equal weight proportions of common licorice roots Glycyrrhiza glabra, parviflorous yarrow herb Achillea micrantha and sandy everlasting blossom Helichrisum arenarium. The tea is extracted in prepared 40% aqueous surgical ethanol in the relation of 1 portion of the raw material to 3 portions of ethanol and kept with agitation for 6 days. Then the mixture is added with an equal proportion of a buffer containing, wt %: calcium chloride 0.014, potassium chloride 0.04, potassium dihydrogen phosphate 0.006, magnesium sulphate 0.02, magnesium chloride 0.02, sodium chloride 0.08, sodium bicarbonate 0.035, disodium phosphate 0.024, glucose 0.1. The mixture is kept for another 4 days in a cool place with daily stirring, filtered andoclaved for three times at 0.5 atm for 10 minutes; the prepared extract is introduced into experimental animals in dose 0.4-0.6 mg/kg of body weight daily through a probe into oesophagus.

EFFECT: presented invention provides higher therapeutic effectiveness ensured by substantial suppression of leprous mycobacteria growth in mice pads, higher activity of completed phagocytosis M leprae in animal macrophagues, optimal selection of doses with no side effects.

5 ex, 10 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically dermatology, and may be used for treating experimental leprous infection. For the purpose for suppression of leprous mycobacteria propagation in mice pads infected intraplantarily by Shepard's method, therapeutic agents are used. The therapeutic agents are presented by a herbal tea. The tea contains ground equal weight proportions of common licorice roots Glycyrrhiza glabra, parviflorous yarrow herb Achillea micrantha and sandy everlasting blossom Helichrisum arenarium. The tea is extracted in prepared 40% aqueous surgical ethanol in the relation of 1 portion of the raw material to 3 portions of ethanol and kept with agitation for 6 days. Then the mixture is added with an equal proportion of a buffer containing, wt %: calcium chloride 0.014, potassium chloride 0.04, potassium dihydrogen phosphate 0.006, magnesium sulphate 0.02, magnesium chloride 0.02, sodium chloride 0.08, sodium bicarbonate 0.035, disodium phosphate 0.024, glucose 0.1. The mixture is kept for another 4 days in a cool place with daily stirring, filtered andoclaved for three times at 0.5 atm for 10 minutes; the prepared extract is introduced into experimental animals in dose 0.4-0.6 mg/kg of body weight daily through a probe into oesophagus.

EFFECT: presented invention provides higher therapeutic effectiveness ensured by substantial suppression of leprous mycobacteria growth in mice pads, higher activity of completed phagocytosis M leprae in animal macrophagues, optimal selection of doses with no side effects.

5 ex, 10 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely pharmacy, and may be used for treating inflammatory periodontal diseases (IPD). The presented agent for treating inflammatory periodontal diseases contains chlorhexidine and aminocapronic acid as active substances and an ointment basis which consists of Vaseline oil, Cremophore RH-40, emulsifier T-2, Lutrol F-127 and purified water in the following proportions, wt %: 20% chlorhexidine - 0.25; aminocapronic acid - 5; emulsifier T-2 - 12; Lutrol F-127 - 10; Vaseline oil - 28; Cremophore RH-40 - 10; purified water - to 100. The agent is presented in the form of an ointment which is easy to use, uniformly distributed on gums, exhibits good fixation and prolonged action.

EFFECT: composition of the agent provides manifested antibacterial, anti-inflammatory and antihemorrhagic action in treating IPD.

2 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology and may be used for drug-induced therapy following recurrent refractive operations. Criteria for drug-induced correction are patient's age, as well as tear break-up time scores, corneal colour, corneal thickness, degree of astigmatism, PRDX6 concentration, presence or absence of gamma-globulin evaluated after recurrent surgical operations. The derived values are used to select drug-induced therapy.

EFFECT: method provides optimising the ocular surface state following recurrent refractive operation.

5 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology and may be used for drug-induced therapy following recurrent refractive operations. Criteria for drug-induced correction are patient's age, as well as tear break-up time scores, corneal colour, corneal thickness, degree of astigmatism, PRDX6 concentration, presence or absence of gamma-globulin evaluated after recurrent surgical operations. The derived values are used to select drug-induced therapy.

EFFECT: method provides optimising the ocular surface state following recurrent refractive operation.

5 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology and may be used for drug-induced therapy following recurrent refractive operations. Criteria for drug-induced correction are patient's age, as well as tear break-up time scores, corneal colour, corneal thickness, degree of astigmatism, PRDX6 concentration, presence or absence of gamma-globulin evaluated after recurrent surgical operations. The derived values are used to select drug-induced therapy.

EFFECT: method provides optimising the ocular surface state following recurrent refractive operation.

5 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology and may be used for drug-induced therapy following recurrent refractive operations. Criteria for drug-induced correction are patient's age, as well as tear break-up time scores, corneal colour, corneal thickness, degree of astigmatism, PRDX6 concentration, presence or absence of gamma-globulin evaluated after recurrent surgical operations. The derived values are used to select drug-induced therapy.

EFFECT: method provides optimising the ocular surface state following recurrent refractive operation.

5 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology and may be used for drug-induced therapy following recurrent refractive operations. Criteria for drug-induced correction are patient's age, as well as tear break-up time scores, corneal colour, corneal thickness, degree of astigmatism, PRDX6 concentration, presence or absence of gamma-globulin evaluated after recurrent surgical operations. The derived values are used to select drug-induced therapy.

EFFECT: method provides optimising the ocular surface state following recurrent refractive operation.

5 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology and may be used for drug-induced therapy following recurrent refractive operations. Criteria for drug-induced correction are patient's age, as well as tear break-up time scores, corneal colour, corneal thickness, degree of astigmatism, PRDX6 concentration, presence or absence of gamma-globulin evaluated after recurrent surgical operations. The derived values are used to select drug-induced therapy.

EFFECT: method provides optimising the ocular surface state following recurrent refractive operation.

5 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology and may be used for drug-induced therapy following a first stage of refractive operation. Criteria for drug-induced correction are patient's age, as well as tear break-up time scores, corneal colour, corneal thickness, degree of astigmatism, antioxidant and immune lachrymal activity - PRDX6 concentration, presence or absence of gamma-globulin evaluated after the primary surgical operation. The derived values are used to select a preparation.

EFFECT: method provides optimising the ocular surface state following the primary refractive operation.

5 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: present invention refers to new oral compositions containing irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more molecules of aliphatic carboxylic acids which activate parietal cells wherein the derivatives induce a delayed or prolonged effect of PPI activity intensification as compared with modified acid molecules.

EFFECT: invention additionally refers to a method for applying such compositions for gastric acid secretion reduction in a mammal.

17 cl, 3 ex, 2 dwg

Up!